JPRN-UMIN000024148已完成1 期
A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis - Phase I/II study of GnP + IP PTX
Department of Gastroenterology, The University of Tokyo0 个研究点目标入组 53 人开始时间: 2017年1月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) contraindication for gemcitabine, nab-paclitaxel or paclitaxel 2) other active concomitant malignancies 3) allergy to iodine or gadolinium contrast agent 4) Blood transfusion or usege of G-CSF within 7 days before enrollment 5) past or current severe heart disease, liver cirrhosis, active GI ulcers or obstruction 6) severe complications such as interstitial pneumonitis, pulmonary fibrosis 7) uncontrollable diabetes mellitus 8) grade 3/4 of sensory neuropathy 9) active infection rather than HBV/HCV 11) pregnant or nursing women 12) judged to be unfit to participate in this study by investigators
研究者
相似试验
进行中（未招募）
1 期
Phase I/II study of GnPipPTXJPRN-jRCTs031180095akai Yousuke44
已完成
不适用
A combination phase I/II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancerpreviously untreated elderly non-small cell lung cancerJPRN-C000000072West Japan Oncology Group25
已完成
不适用
Phase 2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancerung squamous cell carcinomaJPRN-UMIN000004833First Department of Surgery, Hamamatsu University School of Medicine25
进行中（未招募）
2 期
GABARNANCE TrialJPRN-jRCTs031180319Ikeda Masafumi110
招募中
2 期
Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancerBorderline Resectable Pancreatic CancerJPRN-UMIN000026858EPOC A1601/JASPAC07110